Unknown

Dataset Information

0

Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma.


ABSTRACT:

Background

We investigated the prognostic significance of B-cell differentiation status and common B-cell differentiation markers in a post hoc analysis of 119 patients with primary CNS lymphoma (PCNSL) homogeneously receiving high-dose methotrexate (HDMTX)-based chemotherapy within the prospective G-PCNSL-SG1 trial.

Methods

We evaluated protein expression of B-cell lymphoma 2 (BCL2), BCL6, CD10, and multiple myeloma oncogene 1/interferon regulatory factor 4 (MUM1/IRF4) by immunohistochemistry and analyzed the association with survival.

Results

The median follow-up of all patients was 67.5 months. Median progression-free survival (PFS) was 10.61 months (95% CI: 4.23-17.00). Median overall survival (OS) was 28.85 months (95% CI: 17.96-39.73). Eighty-nine tumors expressed BCL2 (92.7%), 24 (20.5%) expressed CD10, 60 (54.1%) expressed BCL6, and 87 (79.0%) expressed MUM1/IRF4. On the basis of the Hans algorithm, 80 tumors (73.4%) were classified to the non-germinal center B group, suggesting a post-germinal center origin of PCNSL. Expression of BCL6 (cutoff point 30%), but none of the other markers, was associated with shorter PFS (P = .047) and OS (P = .035). On multivariate analysis, BCL6 expression was associated with shorter PFS (hazard ratio: 1.95, 95% CI: 1.22-3.12, P = .005) but not OS (hazard ratio: 1.85, 95% CI: 0.71-4.80, P = .21). Classification according to Hans algorithm and expression status of the single B-cell markers BCL2, CD10, and MUM1/IRF4 did not correlate with prognosis.

Conclusion

The findings are limited by the fact that only 23% of all G-PCNSL-SG1 patients could be included in the analysis. If validated in an independent cohort, BCL6 may assume clinical relevance as an unfavorable prognostic biomarker in PCNSL.

SUBMITTER: Kreher S 

PROVIDER: S-EPMC5654355 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>We investigated the prognostic significance of B-cell differentiation status and common B-cell differentiation markers in a post hoc analysis of 119 patients with primary CNS lymphoma (PCNSL) homogeneously receiving high-dose methotrexate (HDMTX)-based chemotherapy within the prospective G-PCNSL-SG1 trial.<h4>Methods</h4>We evaluated protein expression of B-cell lymphoma 2 (BCL2), BCL6, CD10, and multiple myeloma oncogene 1/interferon regulatory factor 4 (MUM1/IRF4) by immunoh  ...[more]

Similar Datasets

| S-EPMC5516483 | biostudies-literature
| S-EPMC4180029 | biostudies-literature
| S-EPMC11355736 | biostudies-literature
2015-07-01 | E-GEOD-61556 | biostudies-arrayexpress
2015-07-01 | GSE61556 | GEO
| S-EPMC7352658 | biostudies-literature
| S-EPMC5571650 | biostudies-literature
| S-EPMC1895776 | biostudies-literature
| S-EPMC5119979 | biostudies-literature
| S-EPMC3362327 | biostudies-literature